FindTrial
Sign In

Efficacy and safety of concomitant use of three immunosuppressant therapy for anti-MDA5 antibody-positive dermatomyositis with interstitial pneumonia

Efficacy and safety of concomitant use of three immunosuppressant therapy for anti-MDA5 antibody-positive dermatomyositis with interstitial pneumonia - Therapy for anti-MDA5 antibody positive interstitial pneumonia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014344
Enrollment
25
Registered
2014-07-01
Start date
2014-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dermatomyositis with interstitial pneumonia

Interventions

Efficacy and safety of concomitant use of three immunosuppressant therapy for anti-MDA5 antibody-positive dermatomyositis with interstitial pneumonia

Sponsors

Kyoto University Graduate School of Medicine
Lead Sponsor
Osaka Red Cross Hospital Kitano Hospital Tenri Hospital Hiroshima University Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Dermatomyositis with anti-MDA5 antibody-positive interstitial pneumonia

Exclusion criteria

Exclusion criteria: Patients who have active tuberculosis or hepatitis B virus infection. Patients who have malignancy when dermatomyositis is diagnosed. Patients under 16 years old.

Design outcomes

Primary

MeasureTime frame
Probability of survival at 6 month and safety.—

Secondary

MeasureTime frame
Change of symptom, biomarker (ferritin, IL-6, IL-18, M-CSF), titer of anti-MDA5 antibody, and chest CT.—

Countries

Japan

Contacts

Public ContactRan Sasai-Nakashima

Kyoto University Graduate School of Medicine Rheumatology and Clinical Immunology

ranran@kuhp.kyoto-u.ac.jp075-751-3793

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026